1. Home
  2. CAPR vs GLP Comparison

CAPR vs GLP Comparison

Compare CAPR & GLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

SELL

Current Price

$26.78

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Logo Global Partners LP

GLP

Global Partners LP

HOLD

Current Price

$49.26

Market Cap

1.6B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAPR
GLP
Founded
2005
2005
Country
United States
United States
Employees
N/A
4700
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Oil Refining/Marketing
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
CAPR
GLP
Price
$26.78
$49.26
Analyst Decision
Strong Buy
Hold
Analyst Count
8
1
Target Price
$44.63
$46.00
AVG Volume (30 Days)
950.2K
79.2K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
6.40%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$64.13
Revenue Next Year
$3.31
$11.74
P/E Ratio
N/A
$23.28
Revenue Growth
N/A
N/A
52 Week Low
$4.30
$39.58
52 Week High
$40.37
$56.51

Technical Indicators

Market Signals
Indicator
CAPR
GLP
Relative Strength Index (RSI) 37.76 53.87
Support Level $25.76 $45.18
Resistance Level $30.21 N/A
Average True Range (ATR) 1.25 1.67
MACD -0.15 -0.08
Stochastic Oscillator 5.05 50.27

Price Performance

Historical Comparison
CAPR
GLP

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About GLP Global Partners LP

Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the GDSO segment.

Share on Social Networks: